Minimal hepatic encephalopathy (MHE) is a subclinical complication of liver cirrhosis with a relevant social impact. Thus, there is urgent need to implement easy to use diagnostic tools for the early identification of affected patients. This study was aimed to investigate cerebral blood flow, systemic hemodynamics as well as endothelial function of cirrhotic patients with MHE, and to verify their change after treatment with rifaximin.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Quantification of middle cerebral artery resistive index
Timeframe: baseline
Quantification of middle cerebral artery pulsatility index
Timeframe: baseline
Quantification of posterior cerebral artery resistive index
Timeframe: baseline
Quantification of posterior cerebral artery pulsatility index
Timeframe: baseline
Change in middle cerebral artery resistive index after treatment with rifaximin
Timeframe: at the end of rifaximin treatment (15 days)
Change in middle cerebral artery pulsatility index after treatment with rifaximin
Timeframe: at the end of rifaximin treatment (15 days)
Change in posterior cerebral artery resistive index after treatment with rifaximin
Timeframe: at the end of rifaximin treatment (15 days)
Change in posterior cerebral artery pulsatility index after treatment with rifaximin
Timeframe: at the end of rifaximin treatment (15 days)